Nuvectis Pharma, Inc. (NVCT)
| Previous close | 12.36 |
| Open | 12.14 |
| Bid | 11.83 x 1100 |
| Ask | 19.20 x 800 |
| Day's range | 11.50 - 12.32 |
| 52-week range | 6.21 - 20.92 |
| Volume | |
| Avg. volume | 62,522 |
| Market cap | 181.012M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.65 |
| Earnings date | 07 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting
Fort Lee, NJ, March 17, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP800 and NXP900 at the upcoming 2023 American Association for Cancer Research Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Flori
- GlobeNewswire
Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference
FORT LEE, NJ, March 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 35th Annual Roth Conference. Event 35th Annual Roth Conference Date March 14, 2023 Time 12:00 PM Pacific Time (3:00 PM Easter
- Simply Wall St.
Bullish insiders bet US$1.1m on Nuvectis Pharma, Inc. (NASDAQ:NVCT)
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
